IP Library Granted Patent US 8,895,241
Granted Patent B2
US 8,895,241 · App. 13/417,035 · Granted Nov 25, 2014

Aptamers for

Inventors: Urs Ochsner (Denver, CO); Evaldas Katilius (Superior, CO); Nebojsa Janjic (Boulder, CO)
Assignee: SomaLogic, Inc.
C12N15/115C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,241
App. No.
13/417,035
Granted
Nov 25, 2014
Kind
B2
Abstract

The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to toxins produced by Clostridium difficile ; diagnostic kits and methods comprising such aptamers; and methods of making and using such aptamers.

Claims (6)

1. A method of detecting the presence of C. difficle toxin in a test sample comprising contacting said test sample with an aptamer that binds to C. difficile toxin B wherein said aptamer comprises a sequence selected from the group consisting of SEQ ID NOS: 67-71.

2. The method of claim 1 , wherein said aptamer further comprises at least one addition chemical modification, wherein said at least one addition chemical modification is a chemical substitution at one or more position independently selected from the group consisting of a ribose position, a deoxyribose position, a phosphate position, and a base position.

3. The method of claim 2 , wherein said at least one additional chemical modification is independently selected from the group consisting of a 2′-amino (2′-NH 2 ), a 2′-fluoro (2′-F), a 2′-O-methyl (2′-Ome), a modification at a cytosine exocyclic amine, a substitution of 5-bromouracil, a substitution of 5-bromodeoxyuridine, a substitution of 5-bromodeoxycytidine, a backbone modification, methylation, a 3′ cap, and a 5′ cap.

4. The method of claim 1 , wherein said aptamer comprises a K d for C. difficile toxin B of 30 nM or less.

5. The method of claim 1 , wherein said aptamer is nuclease resistant.

6. The method claim 1 , wherein said aptamer has a slow off rate.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 20, 2021
From: MADRYN HEALTH PARTNERS, LP, FORMERLY VISIUM HEALTHCARE PARTNERS, LP
To: SOMALOGIC, INC.
Reel/Frame 055981/0884 →
CHANGE OF NAME Recorded Mar 8, 2017
From: VISIUM HEALTHCARE PARTNERS, LP
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 041920/0957 →
SECURITY INTEREST Recorded Feb 29, 2016
From: SOMALOGIC, INC.
To: VISIUM HEALTHCARE PARTNERS, LP
Reel/Frame 037853/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2012
From: OCHSNER, URS; KATILIUS, EVALDAS; JANJIC, NEBOJSA
To: SOMALOGIC, INC.
Reel/Frame 028347/0191 →
Continuity (2)
Provisional Application 61451227 · Mar 10, 2011
Related Publication 20120231467A1 · Sep 13, 2012